Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies by van Griensven, J et al.
Supplementary Appendix
This appendix has been provided by the authors to give readers additional information about their work.
Supplement to: van Griensven J, Edwards T, Baize S. Efficacy of convalescent plasma in relation to dose of Ebola 
virus antibodies. N Engl J Med. DOI: 10.1056/NEJMc1609116
Supplementary Appendix. 
Efficacy of Convalescent Plasma with the Dose of Ebola Virus Antibodies 
Johan van Griensven, M.D., Ph.D.,1 Tansy Edwards, M.Math, M.Sc.2 Sylvain Baize, Ph.D.3 
and the Ebola-Tx Consortium 
 
1Institute of Tropical Medicine, Antwerp, Belgium 
2London School of Hygiene & Tropical Medicine, London, United Kingdom 
3Institut Pasteur, Lyon, France 
2 
 
 
Table of Contents 
Ebola-Tx Consortium collaborators      page 2 
1. Methods 
1.1 Laboratory analysis         page 5 
1.2 Statistical analysis        page 6 
2. Results  
2.1 Description of antibody levels      page 9 
2.2 Association of antibody levels with survival      page 9 
2.3 Association of antibody levels with change in cycle threshold   page 9  
values in EVD patients 
2.4 Association between the amount of antibodies received and PCR              page 9 
 cycle threshold value after transfusion  
References         page 11 
Tables          page 12 
Figure          page 20 
 
  
3 
 
The Ebola-Tx Consortium 
Johan van Griensven, M.D., Ph.D.,1 Tansy Edwards, MMATH, M.Sc.,2 Xavier de Lamballerie, 
M.D., Ph.D.,3,4 Malcolm G. Semple, M.D., Ph.D.,5 Pierre Gallian, Ph.D.,3,4,6 Sylvain Baize, Ph.D.,7 
Peter W. Horby, M.D., Ph.D,8 Hervé Raoul, Ph.D.,9 Magassouba N’Faly, Ph.D.,10 Annick 
Antierens, M.D.,11 Carolyn Lomas, M.D., 11 Ousmane Faye, Ph.D.,12 Amadou Alpha Sall, Ph.D.,12 
Katrien Fransen, M.Sc.,1 Jozefien Buyze, Ph.D.,1 Raffaella Ravinetto, Pharm.D.,1,16 Pierre 
Tiberghien, M.D., Ph.D.,6,13 Yves Claeys, M.Sc.,1 Maaike De Crop, M.Sc.,1 Lutgarde Lynen, M.D., 
Ph.D.,1 Elhadj Ibrahima Bah, M.D.,11 Peter G. Smith, D.Sc.,2 Alexandre Delamou. M.D.,14 Anja 
De Weggheleire, M.D.,1 Nyankoye Haba, M.Sc.,15 and the Ebola-Tx Consortium 
 
1Institute of Tropical Medicine, Antwerp, Belgium 
2 MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, United 
Kingdom 
3Aix Marseille University, IRD French Institute of Research for Development, EHESP French 
School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", Marseille, 
France. 
4IHU Institut Hospitalo-Universitaire Méditerranée Infection, APHM Public Hospitals of 
Marseille, Marseille, France. 
5Institute of Translational Medicine, University of Liverpool, United Kingdom 
6Etablissement Français du Sang, La Plaine St-Denis, France 
7Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France 
8Centre for Tropical Medicine and Global Health, University of Oxford, United Kingdom 
9Inserm Jean Mérieux BSL4 Laboratory, Institut National de la Santé et de la Recherche 
Médicale, Lyon, France 
10Laboratory of Viral Hemorrhagic Fever, Gamal Abdel Nasser University of Conakry, Guinea  
11Médecins Sans Frontières, Brussels, Belgium 
12Institut Pasteur de Dakar, Dakar, Senegal 
13Université de Franche Comté, Inserm, EFS UMR 1098, Besançon, France 
14National Center for Training and Research in Rural Health of Maferinyah, Forecariah, Guinea 
15National Blood Transfusion Centre, Conakry, Guinea 
16Clinical Pharmacology and Pharmacotherapy Department, KU Leuven, Leuven, Belgium 
 
Additional Ebola-Tx Consortium members’ contributions 
4 
 
Field research coordination:  
Bienvenu Salim Camara, National Blood Transfusion Centre, Conakry, Guinea 
Kadio Jean-Jacques Olivier, National Blood Transfusion Centre, Conakry, Guinea 
Younoussa Ballo, Ministry of Health, Conakry, Guinea 
Keita Sakoba, Coordination nationale de lutte contre Ebola en Guinee, Conakry, Guinea 
Kader Konde, Coordination nationale de lutte contre Ebola en Guinee, Conakry, Guinea 
 
EVD expertise:  
Robert Colebunders, Institute of Tropical Medicine, Antwerp, Belgium 
Jean-Jacques Muyembe, Institut National de Recherche Biomédicale (INRB), Kinshasa, RDC 
 
Statistical support:  
Joris Menten, Institute of Tropical Medicine, Antwerp, Belgium 
Neal Alexander, London School of Hygiene and Tropical Medicine, UK 
 
Trial implementation:  
Steven Van Den Broucke, Institute of Tropical Medicine, Antwerp, Belgium 
Alex Custers, Institute of Tropical Medicine, Antwerp, Belgium 
Sarah Temmerman, Institute of Tropical Medicine, Antwerp, Belgium 
Brecht Ingelbeen, Institute of Tropical Medicine, Antwerp, Belgium 
Diana Arango, Institute of Tropical Medicine, Antwerp, Belgium 
 
Laboratory field support:  
Tania Crucitti, Institute of Tropical Medicine, Antwerp, Belgium 
Jan Jacobs, Institute of Tropical Medicine, Antwerp, Belgium 
Vicky Cuylaerts, Institute of Tropical Medicine, Antwerp, Belgium 
Tine Vermoessen, Institute of Tropical Medicine, Antwerp, Belgium 
 
Laboratory testing BSL4 (Lyon, France):  
Caroline Picard, Institut Pasteur, Centre International de Recherche en Infectiologie, Lyon 
Alexandra Fizet, Institut Pasteur, Centre International de Recherche en Infectiologie, Lyon 
Héloïse Thomasset, Institut Pasteur, Centre International de Recherche en Infectiologie, Lyon 
 
Anthropological support 
5 
 
Maya Ronse, Institute of Tropical Medicine, Antwerp, Belgium 
Almudena Mari Saez,  Institute of Tropical Medicine, Antwerp, Belgium & Institute of Tropical 
Medicine and International Health, Charité- Universitätsmedizin Berlin, Germany 
 
Plasmapheresis set-up and training 
Fréderic Bigey, Etablissement Français du Sang Alsace, France 
Mustapha Briki, Etablissement Français du Sang Alpes-Méditerranée, France 
Elise Chambe, Etablissement Français du Sang Bourgogne Franche-Comté, France 
Patricia Chavarin, Etablissement Français du Sang Auvergne-Loire, France 
Myriam Devillers, Etablissement Français du Sang Bourgogne Franche-Comté, France 
Mireille Gauthier, Etablissement Français du Sang Bourgogne Franche-Comté, France 
Alain Guillard, Etablissement Français du Sang Bretagne, France 
Hervé Isola, Etablissement Français du Sang Alsace, France 
Chantal Jacquot, Etablissement Français du Sang La Plaine Stade de France, France 
Brigitte Lardin, Etablissement Français du Sang Bourgogne Franche-Comté, France 
Virginie Lavedrine, Etablissement Français du Sang Alpes-Méditerranée, France 
Catherine Lazaygues, Etablissement Français du Sang Alpes-Méditerranée, France 
Philippe Van de Kerckhove, Belgian Red Cross Flanders, Belgium 
Monique Gueguen, Médecins Sans Frontières, France 
 
Trial coordination at MSF site: 
Sylvie Jonckheere, Médecins Sans Frontières, Belgium 
Hilde Brun Andersen, Médecins Sans Frontières, Belgium  
 
  
6 
 
1. Methods 
1.1 Laboratory methods 
EBOV-specific IgM and IgG detection by Enzyme linked immunosorbent assay (ELISA) 
The antigens used for the Ebola virus (EBOV)-specific IgM and IgG detection were obtained from a viral 
stock of Zaire Ebolavirus (Gabon 2001 strain). Briefly, for IgG detection, 96-well Maxisorp plates (Nunc) 
were coated with EBOV antigen, followed by incubation of several dilutions of patient’s plasma (from 
1:200 to 1:25,000). An anti-human IgG (-chain specific) conjugated with peroxydase (Sigma) was then 
added, and TMB  was used for revelation. IgM was detected using a capture ELISA. An anti-human IgM 
(µ-specific) (Sigma) was coated in 96-well Maxisorp plates, followed by incubation of several dilutions of 
patient’s plasma (from 1:100 to 1:6,400). Then, EBOV antigen was incubated, followed by a polyclonal 
EBOV-specific mouse ascitic immune fluid and a peroxydase-conjugated anti mouse IgG (Sigma). TMB 
(KPL, Eurobio) was used as revelator and the optical density (OD) quantified using a plate reader. 
 
Quantification of EBOV-neutralizing antibodies in donors: Plaque neutralization assay 
Donor plasma was diluted 1:10, 1:40, 1:160, and 1:640 and incubated for 1h at 37°C with EBOV 
(Makona strain) in DMEM supplemented with 2% FCS and 1% penicillin/streptomycin (Invitrogen). A 
neutralizing monoclonal antibody directed against EBOV glycoprotein (kindly provided by L. Bellanger, 
CEA, Marcoule) was used as a positive control and incubated with EBOV at concentrations allowing 
100% and 50% viral neutralization. Plasma from healthy donors were used as negative controls. These 
viral suspensions were then transferred onto confluent Vero E6 cells cultured in 12-well plates. DMEM 
supplemented with 1.6% carboxy-methyl-cellulose (Sigma), 2% FCS, and 1% penicillin/streptomycin was 
added to cells and the plates were incubated at 37°C and 5% CO2. Infectious foci were detected after 
seven days of culture, by incubation with a pool of monoclonal antibodies directed against EBOV 
glycoprotein (generously provided by L. Bellanger, CEA) followed by alkaline phosphatase anti-mouse 
IgG (Sigma) and nitro-blue tetrazolium - 5-bromo-4-chloro-3'-indolyphosphate (Thermo-Fisher). The 
foci were counted in each well and the dilutions of plasma for which a neutralization of more than 50% 
of the viral inoculum were obtained were considered positive. 
 
1.2 Statistical analysis 
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Antibody levels of titers for total anti-EBOV IgG ELISA and plaque neutralization assays were recorded 
for the 85 distinct donations made by 58 donors.  
As specified in the analysis plan, we estimated a total dose of anti-EBOV antibodies received that would 
account for both the antibody level in each plasma treatment unit and volume of plasma received. For 
each antibody measure, the dose a patient received in each transfusion was calculated by multiplying the 
volume of the plasma of each unit transfused by the corresponding antibody level in the unit (ELISA 
optical density value in the 1/200 dilution for total anti-EBOV IgG; titer value from the plaque 
neutralizing assay for the neutralizing antibodies). Most patients received two transfusions from different 
donors so the sum of these doses for each unit a patient received was then calculated to give the 
estimated total antibody dose given per patient.  
Where multiple plasma treatment units were used from the same donor, the contribution of antibody 
levels to total dose received would be the same but the volume transfused would result in different total 
doses received. Use of more plasma treatment units from donors with relatively higher or relatively lower 
antibody levels is accounted for in the total dose measure. Pre-selection of donations from donors with 
higher levels of titers was not possible and the protocol stated that patients were to receive two 
transfusions where transfused units came from different donors. 
 
Effect of total dose on mortality:  
Of the 84 patients in the primary analysis population receiving convalescent plasma, 71 were aged 16 
years and over and were defined as the analysis population to investigate associations between antibody 
dose received and mortality. Children were excluded post-hoc from the analysis of the effect of total dose 
on mortality as dosing of convalescent plasma was done according to body weight; as body weight was 
not recorded for many adult patients, body weight could not be included in analysis to account for the 
lower body weight and body weight adjusted dosing of convalescent plasma in children. Baseline data for 
sex, age and cycle threshold were summarized as the number (%) of patients with each characteristic and 
the median (range) of values for each dose category.  Chi-squared tests and Wilcoxon rank sum tests were 
used to compare data between dose categories for each antibody measure. 
The statistical analysis plan for the main trial pre-specified an analysis of dose response effects for 
mortality and for change in cycle threshold pre- and post-transfusion. We hypothesized that higher total 
doses of anti-EBOV titer received would lead to increased survival and the clearest way to see this would 
be through analysis of data by categories of dose. Given the limited number of patients in our study, 
tertiles seemed a reasonable approach, with more easily interpretable results. Consequently, the total dose 
for each antibody measure (NA50 and IgG) was categorized in to three equal-sized groups (tertiles; dose 
category 1 (Q1), 2 (Q2) and 3 (Q3); dose category 1 being the lowest).  
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Logistic regression models were used to estimate the odds of mortality comparing dose categories 2 and 3 
to category 1, after adjustment for cycle threshold category at baseline and age as a linear effect. To test 
our primary hypothesis of increasing benefit with increasing dose, tests for association assuming a linear 
trend were used to examine evidence of increasing benefit with increased total dose by comparing 
adjusted models with and without dose category as a linear term via a likelihood ratio test. We also 
compared adjusted models with and without dose category to test for an overall association between dose 
and mortality. Adjustment for cycle threshold values was by categories (<25, 25-29.9 and ≥30) as per the 
published report of the primary analysis.1 Given the strong correlation between PCR cycle threshold 
values and RNA viral load,2 and that we did not have RNA viral load on a substantial number of patients, 
we used cycle threshold values as an appropriate measure of the amount of virus in the blood. A 
sensitivity analysis repeated the logistic regression as described but using the actual pre-transfusion CT 
value with a linear and quadratic effects for pre-transfusion cycle threshold in place of the categorical 
variable for cycle threshold. 
 
Effect of total dose on change in cycle threshold pre and post transfusion:  
Of 99 patients of all ages who received at least one transfusion of convalescent plasma, 85 were aged 16 
years or older. One patient had missing titer data for one transfusion and two patients had missing data 
for change in cycle threshold data so 83 patients were included in the analysis of change in cycle threshold 
and total dose. Dose category was created by splitting total dose into three equal-sized groups. As per the 
analysis plan, linear regression models were used to estimate the mean change in cycle threshold pre and 
post transfusion comparing dose categories 2 and 3 to category 1, after adjustment for cycle threshold 
category at baseline and a linear age effect. Tests for association assuming a linear trend and overall 
association were performed as described above. 
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2. Results 
2.1 Donors, donations, treatment units and antibody titers 
The median time between discharge from the Ebola treatment unit and the first donation was 4.3 
months, ranging between 2.2 and 10.2 months (Table S1). The total anti-EBOV IgG and neutralizing 
antibody titers are shown in Table S2 for the different analysis groups.  
2.2 Total dose of anti-EBOV antibodies administered to patients. 
For each patient, the amount of anti-EBOV antibodies received was calculated. Since there are no clear 
biological cut-offs, the total dose was categorized by making three groups of equal size (tertiles), 
providing three dose categories (Table S3).  
2.3 Association between the amount of antibodies received and mortality between day 3-16 after 
EVD diagnosis 
There were 71 adult patients included in the mortality analysis. Total anti-EBOV IgG dose category three 
had the highest number of patients with a cycle threshold value < 25. For neutralizing antibodies, dose 
category two had the highest number of patients with a cycle threshold value < 25 (Table S4). The 
difference in cycle threshold values was significant for neutralizing antibodies but not for total anti-
EBOV IgG antibodies.  
For the total anti-EBOV IgG antibodies, a non-significant decreased odds of mortality between the 3rd 
and 16th day after diagnosis was seen for IgG dose tertile category two (OR 0.47; 95% CI 0.14-1.60) and 
three (OR 0.75; 95% CI 0.23-2.43), compared to those in the lowest dose tertile in an unadjusted analysis. 
Adjusting for age and cycle threshold value, minor changes were seen for dose category two (OR 0.46; 
95% CI 0.12-1.82) and dose category three (OR 0.41; 95% CI 0.10-1.75) compared to the lowest tertile. 
The test for association assuming a linear trend was not significant (p-value: 0.206), Table S5.  
In an unadjusted analysis, a non-significant increase in odds of mortality was seen for neutralizing 
antibodies tertile category two (OR 3.22.; 95% CI 0.90-11.5) and three (OR 2.03, 95% CI 0.55-7.48), 
compared to the lowest dose tertile. Adjusting for age and cycle threshold value, this decreased to an OR 
of 1.99 (95% CI 0.44-9.04) for dose category two and an OR of 2.10 (95% CI 0.50-8.86) for dose 
category three. The test for association assuming a linear trend was not significant (p-value: 0.323). 
Including cycle threshold data as a continuous variable made no material difference to the findings (Table 
S6). Similarly, including dose as a continuous variable did not alter the findings. 
2.4 Association between the amount of antibodies received and PCR cycle threshold value after 
transfusion  
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A total of 83 adults were included in the analysis evaluating the association between dose category and 
change in cycle threshold values pre and post transfusion, adjusting for pre-transfusion values and age 
(Table S7). Higher IgG doses were associated with larger increases in cycle threshold values post-
transfusion (p-value: 0.019) (Table S8). However, there was little difference between the two higher dose 
categories and only weak evidence of a linear trend overall (p-value: 0.056). There was no association 
apparent with the total dose of neutralizing antibodies. Analyzing dose response as continuous variable 
made no material difference to the findings here either.  
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Table S1. Information on donors and donations collected with titer data available  
Characteristic All distinct donations 
n (%) or median (range) 
Number of donors 58 
one donation 37 
≥ 2 donations 21 
Sex  
Male  36 (62) 
Female 22 (38) 
Age, years 29 (18-55) 
Time between discharge and first donation, months 4.3 (2.2-10.2) 
Number of donations*  85 
Time between donation and EVD cure (all donations)   
2-3 months  34 (40) 
4-5 months  33 (39) 
≥6 months  18 (21) 
  EVD: Ebola Virus Disease; IQR: interquartile range 
* 5 donations excluded due to missing titer data  
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Table S2. Titers of total anti-EBOV antibodies in ELISA and of 50% neutralizing antibodies in 
donations during the Ebola-Tx trial 
 Total analyzed CP transfused 
patients in primary 
mortality analysis; 
n=71 aged 16 years 
and above 
CP transfused 
patients with Ct data 
available; n=83 aged 
16 years and above 
Number of donors 58 57 57 
Number of donations 85 78 79 
ELISA  - Titer (IgM)    
Negative  50 (59) 45 (58) 45 (57) 
1/100 17 (20) 17 (22) 17 (22) 
1/400 14 (16) 13 (17) 14 (18) 
1/1600 4 (5) 3 (4) 3 (3) 
ELISA  - Titer (IgG)    
Negative  1 (1) 1 (1) 1 (1) 
1/200 4 (5) 4 (5) 4 (5) 
1/1000 41 (48) 35 (45) 36 (46) 
1/5000 35 (41) 34 (44) 34 (43) 
1/25000 4 (5) 4 (5) 4 (5) 
Plaque neutralization 
assay - Titer (50% 
neutralization) 
Negative  17 (20) 17 (22) 17 (22) 
1/10 34 (40) 29 (37) 30 (38) 
1/40 30 (35) 29 (37) 29 (37) 
1/160 4 (5) 3 (4) 3 (3) 
CP: convalescent plasma; Ct : cycle threshold ; EBOV : Ebola virus 
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Table S3. Total dose ranges for categorization of total doses into 3 equal-sized groups in 71 
patients aged 16 years or over that were treated with convalescent plasma 
Dose 
Category 
 Total anti-EBOV IgG 
antibodies 
Neutralizing antibodies 
 N Median Range Median Range 
1 (Q1) 24 354.1 (176.4 - 511.9) 207.5 (0 - 404)* 
2 (Q2) 24 611.5 (513.3 - 740.6) 925.5 (405 - 1067) 
3 (Q3) 23 971.0 (747.9 - 1628.7) 1620 (1080 - 6528) 
* four zero values 
The total dose for each antibody measure was categorized in to three equal-sized groups (tertiles; dose 
category 1 (Q1), 2 (Q2) and 3 (Q3); dose category 1 being the lowest).  
EBOV: Ebola virus  
Total dose calculation formula:  
Total dose (NA50) = (Titer value for NA50/10 x volume of 1st transfusion) + (Titer value for NA50/10 
x  volume of 2nd transfusion)  + (Titer value for NA50/10 x volume of 3rd transfusion)  
Total dose (IgG) = (ELISA optical density value in the 1/200 dilution for IgG x volume of 1st 
transfusion) + (ELISA optical density value in the 1/200 dilution for IgG x volume of 2nd transfusion) + 
(ELISA optical density value in the 1/200 dilution for IgG x volume of 3rd transfusion)  
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Table S4. Baseline characteristics of 71 patients aged 16 years and above treated with convalescent plasma included in primary mortality analysis in 
relation to the total dose of anti-Ebola virus antibodies received 
 Total dose of anti-EBOV IgG antibodies Total dose of neutralizing antibodies 
 Dose 1 (Q1) 
n=24 
Dose 2 (Q2) 
n=24 
Dose 3 (Q3) 
n=23 
P value Dose 1 (Q1) 
n=24 
Dose 2 (Q2) 
n=24 
Dose 3 (Q3) 
n=23 
P value 
Sex          
Male 10 (42) 10 (42) 11 (48) 0.887 8 (33) 13 (54) 10 (43) 0.347 
Female 14 (58) 14 (58) 12 (52)  16 (67) 11 (46) 13 (57)  
Age (years)*  30.5 (18-75) 30 (16-70) 30 (17-68) 0.316 30 (16-58) 30 (18-74) 30 (17-61) 0.659 
16-44 years 17 (71) 21 (88) 18 (78) 0.366 18 (75) 18 (75) 20 (87) 0.513 
45+ years 7 (29) 3 (12) 5 (22)  6 (25) 6 (25) 3 (13)  
Cycle threshold at 
diagnosis* 
28.9 (19.2-35.8) 28.0 (20.2-35.7) 25.7 (21.0-33.9) 0.160 29.6 (24.5-35.8) 24.9 (19.2-35.1) 26.3 (20.2-35.7) 0.009 
<25 3 (12) 5 (21) 10 (43) 0.129 1 (4) 12 (50) 5 (22) 0.004 
25.0-29.9 13 (54) 12 (50) 10 (43)  15 (63) 6 (25) 14 (61)  
≥30 8 (34) 7 (29) 3 (14)  8 (33) 6 (25) 4 (17)  
* median (range), otherwise data are n (%), p-values from chi-squared test or Kruskall Wallis test. 
The total dose for each antibody measure was categorized in to three equal-sized groups (tertiles; dose category 1 (Q1), 2 (Q2) and 3 (Q3); dose category 1 being 
the lowest).  
EBOV: Ebola virus
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Table S5. Logistic regression of adjusted effect of dose categories on mortality in 71 patients 
aged 16 years and above 
  N Died, n 
(%) 
Adjusted  
OR (95% CI) 
Adjusted  
OR (95% CI) 
Total  71 24 (34)   
      
Age (per yearly increase)   1.06 (1.01-1.11) 1.06 (1.01-1.11) 
      
Cycle 
threshold 
<25.0 18 10 (56) 1 1 
25.0-29.9 35 10 (29) 0.18 (0.04-0.71) 0.27 (0.06-1.16) 
30.0-39.9 18 4 (22) 0.13 (0.02-0.71) 0.23 (0.04-1.13) 
      
Total dose 
anti-EBOV 
IgG 
Q1 24 5 (21) 1 - 
Q2 24 11 (46) 0.46 (0.12-1.82) - 
Q3 23 8 (35) 0.41 (0.10-1.75) - 
      
      
Total dose  
neutralizing 
antibodies  
Q1 24 6 (25) - 1 
Q2 24 8 (33) - 1.99 (0.44-9.04) 
Q3 23 10 (43) - 2.10 (0.50-8.86) 
Overall association between dose category and mortality: LRT p-value comparing adjusted models (cycle 
threshold value and age groups) with and without dose category variable: IgG p = 0.393; NA50 p = 0.543  
Test for association assuming a linear trend after adjustment for age and categorical cycle threshold at 
baseline: Total IgG: p-value=0.206; neutralizing antibodies: p-value=0.323.  
The total dose for each antibody measure was categorized in to three equal-sized groups (tertiles; dose 
category 1 (Q1), 2 (Q2) and 3 (Q3); dose category 1 being the lowest).  
EBOV: Ebola virus; OR: odds ratio; CI: confidence interval 
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Table S6. Mortality analysis with cycle threshold value added as continuous variable with linear 
and quadratic terms, also adjusted for age (as continuous effect)  
  N Died, n 
(%) 
Unadjusted  
OR (95% CI) 
Adjusted  
OR (95% CI) 
  71 24 (34)   
Total dose 
anti-EBOV 
IgG 
Q1 24 6 (25) 1 1 
Q2 24 8 (33) 0.47 (0.14-1.60) 0.45 (0.11-1.95) 
Q3 23 10 (43) 0.75 (0.23-2.43) 0.32 (0.07-1.59) 
      
Total dose 
neutralizing 
antibodies 
Q1 24 5 (21) 1 1 
Q2 24 11 (46) 3.22 (0.90-11.5) 1.43 (0.31-6.68) 
Q3 23 8 (35) 2.03 (0.55-7.48) 1.28 (0.28-5.94) 
The total dose for each antibody measure was categorized in to three equal-sized groups (tertiles; dose 
category 1 (Q1), 2 (Q2) and 3 (Q3); dose category 1 being the lowest).  
EBOV: Ebola virus; OR: odds ratio; CI: confidence interval 
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Table S7. Cycle threshold values before and after transfusion 
 
70 patients* in mortality analysis 
83 patients† in change in cycle 
threshold analysis 
 Mean 
(SD) 
Median (range) Mean (SD) Median (range) 
Pre-transfusion 27.7 (4.1) 27.1 (19.2 to 35.8) 27.5 (4.2) 26.9 (18.5 to 35.8) 
Post-transfusion 31.1 (5.2) 30.3 (21.8 to 41) 30.2 (5.8) 29.8 (14.0 to 41.0) 
Change post-transfusion     
All 3.4 (4.1) 3.4 (-7.2 to 12.5) 2.7 (4.6) 2.9 (-11.9 to 12.5) 
Survived 4.0 (3.7) 3.8 (-2.3 to 12.5) 3.4 (4.3) 3.4 (-11.9 to 12.5) 
Died 2.2 (4.7) 2.2 (-7.2 to 10.5) 1.3 (5.1) 1.9 (-9.5 to 10.5) 
Total dose anti-EBOV IgG 
antibodies 
    
Q1   1.5 (3.7) 1.2 (-7.2 to 7.3) 0.6 (4.4) 0.9 (-9.5 to 7.3) 
Q2  5.4 (4.6) 6.4 (-6.3 to 12.5) 4.2 (5.2) 4.5 (-11.9 to 12.5) 
Q3 3.5 (3.1) 3.5 (-2.3 to 10.5) 3.3 (3.5) 3.5 (-4.0 to 10.5) 
Total dose neutralizing 
antibodies  
    
Q1   2.5 (3.9) 2.0 (-7.2 to 11.2) 2.4 (3.8) 2.1 (-7.2 to 11.2) 
Q2  4.7 (3.7) 4.5 (-2.4 to 10.5) 3.2 (5.7) 3.5 (-11.9 to 10.5) 
Q3 3.1 (4.6) 3.2 (-6.3 to 12.5) 2.5 (4.4) 2.5 (-6.3 to 12.5) 
     * 1 patient had a missing value for cycle threshold post transfusion 
† 2 patients had a missing value for cycle threshold post transfusion, one patient had missing titer data for 
one transfusion 
The total dose for each antibody measure was categorized in to three equal-sized groups (tertiles; dose 
category 1 (Q1), 2 (Q2) and 3 (Q3); dose category 1 being the lowest).  
EBOV: Ebola virus; SD: standard deviation 
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Table S8. Linear regression of change in cycle threshold (Ct) values pre- and post-transfusion, 
adjusted for age and pre-transfusion values (N = 83 patients) 
  Predicted change in Ct value (95% CI), adjusted for age and pre-
transfusion cycle threshold value 
Total dose anti-
EBOV IgG 
antibodies 
Q1 (ref) 
Q2 3.24 (0.87 to 5.61) 
Q3 2.34 (-0.09 to 4.78) 
Total dose 
neutralizing 
antibodies 
Q1 (ref) 
Q2 0.30 (-2.30 to 2.90) 
Q3 -0.46 (-2.99 to 2.08) 
Overall association between dose category and change in Ct value pre and post transfusion: LRT p-value 
comparing adjusted models (pre-transfusion cycle threshold value and age) with and without dose 
category variable: IgG p = 0.019; NA50 p = 0.818.  
Test for association assuming a linear trend after adjustment for age and pre-transfusion cycle threshold 
value: Total IgG: p-value=0.056; neutralizing antibodies: p-value=0.692  
If a post-hoc conservative Bonferroni adjustment for conducting four hypothesis tests (0.05/4 = 0.0125) 
was applied, the overall association for IgG dose response and association assuming a linear trend for IgG 
dose response would not be significant. 
The total dose for each antibody measure was categorized in to three equal-sized groups (tertiles; dose 
category 1 (Q1), 2 (Q2) and 3 (Q3); dose category 1 being the lowest).  
CI: confidence interval 
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Figure S1. Numbers of convalescent plasma donors, donations and treatment units prepared and 
administered   
* There were 93 presentations for donation but on three occasions, a donation could not be made for 
technical reasons. 
 
 
Donors  n = 58
Donations on separate occasions * n = 90
Number of  treatment units n = 241
Titer distribution:
Donors  n = 58
Donations on separate occasions n = 85
Treatment units n = 231
Total dose and change in cycle threshold:
Transfused patients  n = 99
Patients with complete titer information for transfusions 
received n = 98
Donations on separate occasions n = 79 from 57donors
Number of  treatment units n = 189
Patients with complete dose and cycle threshold data n = 96
(83 aged 16 years and over)
Number of  donations 
per donor: one n = 37; 
two n = 16; three n = 4; 
four n = 1
10 treatment units with 
missing values
Total dose and mortality in 
primary analysis population:
Patients n = 84 (71 aged 16 years 
and over, 13 under 16)
Donations on separate occasions n 
= 78 from 57 donors
Number of  treatment units n = 161
